Utility of C-terminal Proendothelin in the Early Diagnosis and Risk Stratification of Patients With Suspected Acute Myocardial Infarction

2014 ◽  
Vol 30 (2) ◽  
pp. 195-203 ◽  
Author(s):  
Philip Haaf ◽  
Christa Zellweger ◽  
Tobias Reichlin ◽  
Anina Zbinden ◽  
Karin Wildi ◽  
...  
Keyword(s):  
Myocardial Infarction ◽  
Acute Myocardial Infarction ◽  
Early Diagnosis ◽  
Risk Stratification ◽  
Suspected Acute Myocardial Infarction

scholarly journals Copeptin Testing in Acute Myocardial Infarction: Ready for Routine Use?

2015 ◽  
Vol 2015 ◽  
pp. 1-9 ◽  
Author(s):  
Sebastian Johannes Reinstadler ◽  
Gert Klug ◽  
Hans-Josef Feistritzer ◽  
Bernhard Metzler ◽  
Johannes Mair
Keyword(s):  
Myocardial Infarction ◽  
Acute Myocardial Infarction ◽  
Risk Stratification ◽  
Myocardial Injury ◽  
Early Stage ◽  
Additional Information ◽  
Acute Myocardial Injury ◽  
Coronary Syndromes ◽  
Suspected Acute Myocardial Infarction ◽  
Cardiac Troponins

Suspected acute myocardial infarction is one of the leading causes of admission to emergency departments. In the last decade, biomarkers revolutionized the management of patients with suspected acute coronary syndromes. Besides their pivotal assistance in timely diagnosis, biomarkers provide additional information for risk stratification. Cardiac troponins I and T are the most sensitive and specific markers of acute myocardial injury. Nonetheless, in order to overcome the remaining limitations of these markers, novel candidate biomarkers sensitive to early stage of disease are being extensively investigated. Among them, copeptin, a stable peptide derived from the precursor of vasopressin, emerged as a promising biomarker for the evaluation of suspected acute myocardial infarction. In this review, we summarize the currently available evidence for the usefulness of copeptin in the diagnosis and risk stratification of patients with suspected acute myocardial infarction in comparison with routine biomarkers.

Sign in / Sign up

Export Citation Format

Share Document